Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
A major Novartis shareholder demands a board restructuring to improve corporate governance after a record share price drop this week. This follows prior investor worries regarding late-phase drug trial failures, long-term capital deployment strategies leading into the 2030s, and a legal defeat for the heart failure treatment Entresto that threatens its patent protection. In addition, European pharmaceutical manufacturers face separate market pressures from cheaper Chinese antibiotic production. This cheap production threatens the Sandoz penicillin plant located in Kundl, Austria, raising broader concerns over European reliance on essential medicine imports.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ A major Novartis shareholder is demanding a board restructuring to improve corporate governance following a record drop in the company share price.
- ✓ European pharmaceutical manufacturers face separate pressures from cheaper Chinese antibiotic production threatening the Sandoz penicillin plant in Kundl, Austria.
What changed
A major Novartis shareholder demanded a board restructuring to improve corporate governance following a record drop in the company share price.
Live updates
-
Novartis Faces Shareholder Pressure Over Board Overhaul
A major Novartis shareholder demands a board restructuring to improve corporate governance after a record share price drop this week. This follows prior investor worries regarding late-phase drug trial failures, long-term capital deployment strategies leading into the 2030s, and a legal defeat for the heart failure treatment Entresto that threatens its patent protection. In addition, European pharmaceutical manufacturers face separate market pressures from cheaper Chinese antibiotic production. This cheap production threatens the Sandoz penicillin plant located in Kundl, Austria, raising broader concerns over European reliance on essential medicine imports.
Why it matters
Governance disputes and drug trial setbacks compound broader structural vulnerabilities in the European pharmaceutical sector. Competition from less expensive international manufacturing threatens domestic supply chains for critical treatments like penicillin. Investors continue to scrutinize corporate leadership and capital allocation as key patents face legal threats.
What is confirmed
- A major Novartis shareholder is demanding a board restructuring to improve corporate governance following a record drop in the company share price.
- European pharmaceutical manufacturers face separate pressures from cheaper Chinese antibiotic production threatening the Sandoz penicillin plant in Kundl, Austria.
What to watch next
- Decisions by Novartis leadership regarding potential board restructuring demands
- Developments concerning the legal protection status of the heart failure treatment Entresto
- Future operational updates regarding the Sandoz penicillin plant in Kundl, Austria
confidence 100%Sources used for this update (10)
- octolens.com — 21 Best Social Listening Tools in 2026 (Compared) - Octolens
- www.xpoz.ai — Best Affordable Social Listening Tools for Small Business
- devta.so — The Best Value Social Listening Tools in 2026 - What to Use at...
- syncly.app — 7 Best Sprout Social Alternatives That Won't Break Your Budget...
- www.buska.io — Best Social Listening Tools 2026: 10 Compared (Free Options)
- forumscout.app — Best Cheap Social Listening Tools in 2026 - forumscout.app
- rawneed.com — Best Social Listening Tools (2026): an Honest, Ranked Guide
- marketintelligencetools.com — Social Listening Tools: Rankings and Buying Guide (2026)
- konnectinsights.com — 21 Best Social Listening Tools in 2026 (Compared)
- listeningplatforms.com — Social Listening Tools Comparison 2026 | Compare Top Platforms | ...
-
Novartis Shareholder Demands Board Overhaul After Setbacks
A major Novartis shareholder is demanding a board restructuring to improve corporate governance following a record drop in the company's share price this week. This shareholder pressure builds on prior investor concerns regarding late-phase drug trial failures, capital deployment strategies leading into the 2030s, and a legal defeat over the heart failure treatment Entresto that threatens patent protection. Meanwhile, European pharmaceutical manufacturers face separate pressures from cheaper Chinese antibiotic production threatening the Sandoz penicillin plant in Kundl, Austria, raising broader concerns over European reliance on essential medicine imports.
Why it matters
Governance demands arrive as the drugmaker confronts severe commercial headwinds, including a court ruling that invalidated a key patent for its blockbuster heart failure therapy Entresto, which generated about 11 percent of company revenues last year. Investors are increasingly questioning management's capital allocation following these legal and research setbacks. Concurrently, European health manufacturing faces external strains from low-cost Chinese imports challenging domestic production facilities.
What is confirmed
- A major Novartis shareholder is demanding a board restructuring to improve corporate governance.
- The company's share price suffered a record drop this week.
Still unconfirmed
- Indian banks are financing up to 75 percent of M&A deal values following central bank rule changes.
What to watch next
- Any formal response from Novartis management or the board regarding the shareholder restructuring demand.
- Further developments concerning the Sandoz penicillin plant in Kundl and European policy responses to Chinese antibiotic imports.
confidence 80%Sources used for this update (2)
- www.bitget.com — Novartis major shareholder calls for board restructuring to ...
- economictimes.indiatimes.com — novartis deal: Latest News & Videos, Photos about novartis ...
-
Novartis Board Faces Scrutiny After Patent Loss and Trial Failures
A major shareholder is demanding a Novartis board overhaul following a series of late-phase drug trial failures and a legal defeat over the heart failure therapy Entresto. A US district court in Delaware ruled patent No. 8,101,659 invalid, potentially opening the door for generic competition in 2025. Entresto generated approximately 11% of company revenues last year. These setbacks, combined with R&D flops, have led investors to question the company's capital deployment and growth strategy leading into the 2030s.
Why it matters
The company recently experienced its worst trading day in over twenty years, with shares dropping 10 percent. This volatility stems from a combination of failed studies for rare muscle diseases and criticized merger and acquisition strategies.
What is confirmed
- A US district court in Delaware ruled that patent No. 8,101,659 for Entresto is invalid.
- Entresto accounted for around 11% of Novartis revenues last year.
- The invalidated patent was scheduled to expire on 15th July 2025.
- Novartis intends to appeal the court's decision regarding the Entresto patent.
Still unconfirmed
- Multiple late-phase trial failures have raised questions about Novartis' capital deployment for growth through the 2030s.
- A major shareholder is calling for a board shake-up following costly drug trial failures.
What to watch next
- Board response to shareholder demands for a shake-up.
confidence 90%Sources used for this update (2)
- convitgroup.com — Novartis’ board faces investor scrutiny after M&A misfires ...
- pharmaphorum.com — Novartis will appeal Entresto patent setback - pharmaphorum
-
Novartis shareholder seeks board overhaul after drug trial setbacks
A major Novartis shareholder is calling for a board shake-up following costly drug trial failures, including a rare muscle disease study setback. Novartis shares plummeted 10 percent in their worst trading day in over twenty years. The shareholder's demand for change is drawing attention to the company's past mergers and acquisitions strategy.
Why it matters
The recent setbacks have raised concerns about Novartis' corporate governance and strategic decisions. The company's shares have been impacted, with a significant drop in value. This has led to increased scrutiny of Novartis' board and leadership.
What is confirmed
- Novartis shares fell 10 percent in their worst trading day in over twenty years.
- A major Novartis shareholder is calling for a comprehensive board overhaul.
- Novartis has recently experienced costly drug trial failures, including a rare muscle disease study setback.
- The shareholder's call for change is turning investor attention to the company's past mergers and acquisitions strategy.
- Novartis entered an RNA agreement worth up to $7.8 billion.
Still unconfirmed
- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG.
What to watch next
- Novartis board response to shareholder demands
- Outcome of ongoing investigations into Novartis
- Impact on Novartis' future mergers and acquisitions strategy
confidence 80%Sources used for this update (8)
- www.marketbeat.com — NVS News Today | Why did Novartis stock go down today?
- www.pharmexec.com — Operations | Topic | PharmExec
- finance.yahoo.com — Novartis Stocks Stay Flat as $575 Million RNA Bet Opens $7.2 ...
- www.prnewswire.com — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On ...
- www.ad-hoc-news.de — Novartis stock falls 1.46 percent after Abogen deal announcement
- live.euronext.com — Exclusive-Major Novartis shareholder calls for board shake-up ...
- www.distillintelligence.com — Latest Novartis News & Announcements | Distill
- hk.marketscreener.com — All Transcripts on Novartis AG (NVS) - hk.marketscreener.com
-
Novartis shareholder calls for board overhaul
A major Novartis shareholder is demanding a comprehensive board overhaul following a series of costly drug trial failures, including the latest setback in a rare muscle disease study. This comes after Novartis shares experienced a significant drop, falling 10 percent in their worst trading day in over twenty years. The shareholder's call for change is turning investor attention to the company's past mergers and acquisitions strategy.
Why it matters
Novartis is a Swiss multinational pharmaceutical corporation and one of the largest pharmaceutical companies in the world. The company was formed in 1996 by the merger of Ciba-Geigy and Sandoz, which was considered the largest corporate merger in history at the time. Novartis has a diverse portfolio of products, including innovative prescription medicines and established older brands.
What is confirmed
- Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland.
- Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz.
- Novartis shares fell 10 percent in their worst trading day in over twenty years following a succession of three drug trial failures.
Still unconfirmed
- A major shareholder is demanding a comprehensive board overhaul and shake-up.
What to watch next
- Novartis' response to the shareholder's demands
- The outcome of the company's ongoing drug trials
- The impact on Novartis' mergers and acquisitions strategy
confidence 80%Sources used for this update (12)
- www.opb.org — DOE overhauls the longtime Hanford Nuclear Reservation advisory board
- www.novartis.com — Novartis
- en.wikipedia.org — Novartis - Wikipedia
- www.novartis.com — Novartis Pharmaceuticals United States of America
- novartis.wd3.myworkdayjobs.com — Search for Jobs
- finance.yahoo.com — Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo...
- pap.novartis.com — Novartis Patient Assistance Foundation
- www.forbes.com — Novartis | Company Overview & News - Forbes
- live.novartis.com — 30 Years of Innovation: The Novartis Story
- www.novartis.com — Careers | Novartis
- www.novartis.com — About - Novartis
- www.novartis.com — Investors - Novartis
-
Novartis Shares Plunge After Triple Drug Trial Setbacks
Novartis shares experienced a historic drop, falling 10 percent and clocking their worst trading day in over twenty years following a succession of three drug trial failures within a single week. The most recent blow involved an RNA drug failing to meet expectations in a rare muscle disease study, specifically impacting the late-stage DM1 study for the drug del-desiran. In response to these costly development setbacks, a major shareholder has demanded a comprehensive board overhaul and shake-up, turning investor attention sharply toward past mergers and acquisitions strategy.
Why it matters
The sudden cluster of three trial failures has dealt a severe blow to the pharmaceutical giant's pipeline confidence. These setbacks have also triggered sympathy declines for industry peers like DYN and SRPT. Disappointed investors are now intensely scrutinizing management decisions surrounding recent high-value corporate deals and asset acquisitions.
What is confirmed
- Novartis shares plummeted 10 percent following three drug trial setbacks within a week.
- The latest trial failure involved the RNA drug del-desiran in a late-stage DM1 study for rare muscle disease.
- A major Novartis shareholder called for a board overhaul and shake-up following the costly deal and trial setbacks.
What to watch next
- Any formal response from the Novartis board regarding the shareholder's call for an overhaul
- Further market reactions and stock performance updates for Novartis and peer companies like DYN and SRPT
confidence 100%Sources used for this update (11)
- CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
- WSJ — Novartis’s Latest Trial Setback Sinks Stock
- Bloomberg.com — Novartis Sees Avidity Drug Fail in Third Setback in a Week
- Yahoo Finance — NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
- BioPharma Dive — Novartis RNA drug falls short in rare muscle disease study
- Fierce Pharma — Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
- Reuters — EXCLUSIVE: Major Novartis shareholder calls for board shake-up after drug trial setbacks
- Yahoo Finance — Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
- Reuters — Novartis investors turn spotlight on M&A after trial setbacks
- FirstWord Pharma — Major shareholder calls for board change at Novartis: report
- BioSpace — Novartis drags peers down with triple asset stumble
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community